Laboratory of Alternative Animal Models, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, 202002, Uttar Pradesh, India.
CNS Neurol Disord Drug Targets. 2024;23(10):1217-1233. doi: 10.2174/0118715273283338240104112106.
Neurodegenerative diseases represent a formidable global health challenge, affecting millions and imposing substantial burdens on healthcare systems worldwide. Conditions, like Alzheimer's, Parkinson's, and Huntington's diseases, among others, share common characteristics, such as neuronal loss, misfolded protein aggregation, and nervous system dysfunction. One of the major obstacles in treating these diseases is the presence of the blood-brain barrier, limiting the delivery of therapeutic agents to the central nervous system. Nanotechnology offers promising solutions to overcome these challenges. In Alzheimer's disease, NPs loaded with various compounds have shown remarkable promise in preventing amyloid-beta (Aβ) aggregation and reducing neurotoxicity. Parkinson's disease benefits from improved dopamine delivery and neuroprotection. Huntington's disease poses its own set of challenges, but nanotechnology continues to offer innovative solutions. The promising developments in nanoparticle-based interventions for neurodegenerative diseases, like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), have offered new avenues for effective treatment. Nanotechnology represents a promising frontier in biomedical research, offering tailored solutions to the complex challenges posed by neurodegenerative diseases. While much progress has been made, ongoing research is essential to optimize nanomaterial designs, improve targeting, and ensure biocompatibility and safety. Nanomaterials possess unique properties that make them excellent candidates for targeted drug delivery and neuroprotection. They can effectively bypass the blood-brain barrier, opening doors to precise drug delivery strategies. This review explores the extensive research on nanoparticles (NPs) and nanocomposites in diagnosing and treating neurodegenerative disorders. These nanomaterials exhibit exceptional abilities to target neurodegenerative processes and halt disease progression.
神经退行性疾病是一项严峻的全球健康挑战,影响着数百万人,并给全球的医疗体系带来了巨大的负担。阿尔茨海默病、帕金森病、亨廷顿病等疾病具有神经元丧失、错误折叠蛋白聚集和神经系统功能障碍等共同特征。治疗这些疾病的主要障碍之一是血脑屏障的存在,限制了治疗剂进入中枢神经系统。纳米技术为克服这些挑战提供了有希望的解决方案。在阿尔茨海默病中,负载各种化合物的纳米颗粒在预防淀粉样蛋白-β(Aβ)聚集和减少神经毒性方面显示出了显著的前景。帕金森病受益于改善多巴胺传递和神经保护。亨廷顿病则存在其自身的挑战,但纳米技术仍在提供创新的解决方案。基于纳米粒子的干预措施在神经退行性疾病中的有希望的发展,如肌萎缩侧索硬化症(ALS)和多发性硬化症(MS),为有效治疗提供了新途径。纳米技术是生物医学研究中一个很有前途的前沿领域,为神经退行性疾病所带来的复杂挑战提供了定制化的解决方案。尽管已经取得了很大的进展,但持续的研究对于优化纳米材料设计、提高靶向性以及确保生物相容性和安全性仍然至关重要。纳米材料具有独特的性质,使其成为靶向药物输送和神经保护的理想候选材料。它们可以有效地绕过血脑屏障,为精确的药物输送策略开辟了道路。这篇综述探讨了纳米粒子(NPs)和纳米复合材料在诊断和治疗神经退行性疾病方面的广泛研究。这些纳米材料具有靶向神经退行性过程和阻止疾病进展的卓越能力。